News
Current report No. 2/2022 – Obtaining information concerning a European patent for esketamine inhalation formulation and expanding patent protection beyond the treatment of treatment-resistant depression
In reference to current report No. 52/2021, the Management Board of Celon Pharma S.A. (“Company”) hereby informs that on January 10, 2022 it received specifications of European patents No. EP 3 731 815 B1 and EP 3 505 157 B1 for esketamine inhalation formulation, the granting of which was announced in “European Patent Bulletin 21/49” of December 8, 2021.
Current report No. 1/2022 – Dates for submitting periodical reports in 2022
Acting pursuant to Article 80 subs. 1 of the Regulation of the Minister of Finance of 29 March 2018 on current and periodic information provided by issuers of securities […], the Management Board of Celon Pharma S.A. announces the dates for submitting periodical reports in 2022
Current report No. 55/2021 – Expansion of the territorial scope of the licence agreement with Glenmark Pharmaceuticals Ltd.
In connection with current report No. 13/2021 K on Celon Pharma S.A. (“Company”) and Glenmark Pharmaceuticals Ltd with its registered seat in India concluding a licence
Current report No. 54/2021 – Signing of an agreement on implementing and co-funding a commercial clinical trial project – development of innovative therapeutic solutions using RNA technology
The Management Board of Celon Pharma S.A. (“Company”, “Beneficiary”) hereby informs that on December 13, 2021 an agreement was signed between the Company and the Medical Research Agency (“Agency”) on implementing and co-funding a commercial clinical trial project – development of innovative therapeutic solutions using RNA technology, entitled: “TransformRNA – mRNA Therapeutics generation platform” (“Agreement” and “Project” or “TransformRNA”, respectively). Information that the aforementioned project was selected for co-funding has been announced by the Company in current report No. 48/2021 on November 29, 2021.
Current report No. 53/2021 – Notification about transactions on shares of Celon Pharma S.A.
The Management Board of Celon Pharma S.A. (the “Company”) hereby informs that on December 9, 2021, Glatton Sp. z o.o. – a person closely related to the person discharging managerial responsibilities, i.e. Mr. Maciej Wieczorek – President of the Management Board of Celon Pharma S.A., sent a notification on transactions conducted on the Company’s shares.
Current report No. 52/2021 – Obtaining a European patent for esketamine inhalation formulation in the treatment of treatment-resistant depression
The Management Board of Celon Pharma S.A. (the “Company”) hereby informs that the Company has been notified today that it has been granted a European patent for the use of esketamine inhalation formulation in the treatment of treatment-resistant depression.
Current report No. 51/2021 – Notification about transactions on shares of Celon Pharma S.A.
The Management Board of Celon Pharma S.A. (the “Company”) hereby informs that on December 3, 2021, Glatton Sp. z o.o. – a person closely related to the person discharging managerial responsibilities, i.e. Mr. Maciej Wieczorek – President of the Management Board of Celon Pharma S.A., sent a notification on transactions conducted on the Company’s shares.
Current report No. 50/2021 – Notification about transactions on shares of Celon Pharma S.A.
The Management Board of Celon Pharma S.A. (the “Company”) hereby informs that on December 1, 2021, Glatton Sp. z o.o. – a person closely related to the person discharging managerial responsibilities, i.e. Mr. Maciej Wieczorek – President of the Management Board of Celon Pharma S.A., sent a notification on transactions conducted on the Company’s shares.
Celon Pharma S.A.’s TransformRNA project received co-financing in the competition organized by the Medical Research Agency
The aim of the competition was to support the development of drug technologies based on nucleic acids (RNA and DNA). As one of the most promising trends in modern biotechnology, they may play a crucial role in ensuring national epidemiological safety and preventing infectious diseases.
Current report No. 49/2021 K – Supplement to current report 49/2021 dated November 30, 2021 concerning the change in the composition of the Management Board of Celon Pharma S.A.
November 30, 2021, hereby forwards a statement of Ms Dorota Zwolińska, appointed on November 30, 2021 by the Company’s Supervisory Board to the Management Board as of December 15, 2021.